Migraine preventive drugs differentially affect cortical spreading depression in rat

Neurobiology of Disease

Volumn 41, Issue 2, 2011, Pages 430-435

  Bogdanov, Volodymyr Borysovych ^a   Multon, Sylvie ^a   Chauvel, Virginie ^a   Bogdanova, Olena Viktorivna ^a,b   Prodanov, Dimiter ^a,c   Makarchuk, Mykola Yukhymovych ^b   Schoenen, Jean ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

^c IMEC   (Belgium)

Author keywords

Cortical spreading depression; Lamotrigine; Migraine; Riboflavin; Valproate

Indexed keywords

DIMETHYL SULFOXIDE; FLAVINE ADENINE NUCLEOTIDE; LAMOTRIGINE; POTASSIUM CHLORIDE; PROTEIN FOS; RIBOFLAVIN; SODIUM CHLORIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH RECORDING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HEADACHE; MALE; MIGRAINE; MIGRAINE AURA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPREADING CORTICAL DEPRESSION; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; CORTICAL SPREADING DEPRESSION; MALE; MIGRAINE DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RIBOFLAVIN; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 78650677272     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.10.014     Document Type: Article

References (64)

1. The International Classification of Headache Disorders. Cephalalgia 2004, 24 Suppl 1:9-160. Headache classification Committee of the International Headache Society. 2nd edition.
2. Akerman S., et al. Mechanically-induced cortical spreading depression associated regional cerebral blood flow changes are blocked by Na+ion channel blockade. Brain Res. 2008, 1229:27-36.
3. Andlin-Sobocki P., et al. Cost of disorders of the brain in Europe. Eur. J. Neurol. 2005, 12(Suppl 1):1-27.
4. Andreou A.P., et al. GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. Neurobiol. Dis. 2010, 37:314-323.
5. Ayata C., et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 2006, 59:652-661.
6. Baf M.H., et al. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem. Int. 1994, 24:67-72.
7. Bergerot A., et al. Animal models of migraine: looking at the component parts of a complex disorder. Eur. J. Neurosci. 2006, 24:1517-1534.
8. Boehnke C., et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur. J. Neurol. 2004, 11:475-477.
9. Bohotin C., et al. Vagus nerve stimulation in awake rats reduces formalin-induced nociceptive behaviour and fos-immunoreactivity in trigeminal nucleus caudalis. Pain 2003, 101:3-12.
10. Bolay H., et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 2002, 8:136-142.
11. Capo-chichi C.D., et al. Analysis of riboflavin and riboflavin cofactor levels in plasma by high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. 2000, 739:219-224.
12. Chebabo S.R., Do Carmo R.J. Phenytoin and retinal spreading depression. Brain Res. 1991, 551:16-19.
13. Chen G., et al. Involvement of kv1 potassium channels in spreading acidification and depression in the cerebellar cortex. J. Neurophysiol. 2005, 94:1287-1298.
14. Chen S., et al. Time-varying spreading depression waves in rat cortex revealed by optical intrinsic signal imaging. Neurosci. Lett. 2006, 396:132-136.
15. Cutrer F.M., et al. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br. J. Pharmacol. 1995, 116:3199-3204.
16. D'Andrea G., et al. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999, 19:64-66.
17. Dietz R.M., et al. Contributions of Ca2+ and Zn2+ to spreading depression-like events and neuronal injury. J. Neurochem. 2009, 109(Suppl 1):145-152.
18. dos Santos A.A., et al. Fluoxetine inhibits cortical spreading depression in weaned and adult rats suckled under favorable and unfavorable lactation conditions. Exp. Neurol. 2006, 200:275-282.
19. Eiselt M., et al. Inhomogeneous propagation of cortical spreading depression-detection by electro- and magnetoencephalography in rats. Brain Res. 2004, 1028:83-91.
20. Evers S., et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur. J. Neurol. 2009, 16:968-981.
21. Fumal A., Schoenen J. Current migraine management - patient acceptability and future approaches. Neuropsychiatr. Dis. Treat. 2008, 4:1043-1057.
22. Goadsby P.J., et al. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009, 29:742-750.
23. Gorelova N.A., et al. Ketamine blockade of cortical spreading depression in rats. Electroencephalogr. Clin. Neurophysiol. 1987, 66:440-447.
24. Hadjikhani N., et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad. Sci. USA 2001, 98:4687-4692.
25. Hauge A.W., et al. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 2009, 8:718-723.
26. Herrera D.G., Robertson H.A. Application of potassium chloride to the brain surface induces the c-fos proto-oncogene: reversal by MK-801. Brain Res. 1990, 510:166-170.
27. Hustad S., et al. Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation. Clin. Chem. 2002, 48:1571-1577.
28. Kaube H., et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000, 55:139-141.
29. Kinze S., et al. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache 2001, 41:774-778.
30. Lampl C., et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J. Neurol. Neurosurg. Psychiatry 2005, 76:1730-1732.
31. Large C.H., et al. The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res. 2009, 85:96-106.
32. Lauritzen M., Olesen J. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 1984, 107(Pt 2):447-461.
33. Leao A.A.P. Spreading depression of activity in the cerebral cortex. J. Neurophysiol. 1944, 7:359-390.
34. Li X., et al. Lamotrigine and valproic acid have different effects on motorcortical neuronal excitability. J. Neural Transm. 2009, 116:423-429.
35. Loscher W. The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia 2007, 48:1245-1258.
36. Martella G., et al. Antiepileptic drugs on calcium currents recorded from cortical and PAG neurons: therapeutic implications for migraine. Cephalalgia 2008, 28:1315-1326.
37. Milner P.M. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leao. Electroencephalogr. Clin. Neurophysiol. 1958, 10:705.
38. Moskowitz M.A. The neurobiology of vascular head pain. Ann. Neurol. 1984, 16:157-168.
39. Moskowitz M.A. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993, 43:S16-S20.
40. Moskowitz M.A., et al. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J. Neurosci. 1993, 13:1167-1177.
41. Nagatsu T., et al. Incorporation of peripherally administered riboflavine into flavine nucleotides in the brain. J. Neurochem. 1967, 14:207-210.
42. Okuda J., et al. Metabolism of injected flavins studied by using double-labeled [14C]flavin adenine dinucleotide and [14C, 32P]flavin mononucleotide. J. Nutr. Sci. Vitaminol. Tokyo 1978, 24:505-510.
43. Olesen J., et al. Spreading cerebral oligemia in classical- and normal cerebral blood flow in common migraine. Headache 1982, 22:242-248.
44. Pascual J., et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache 2004, 44:1024-1028.
45. Paxinos G., Watson C. The rat brain in stereotaxic coordinates/George Paxinos 2007, Charles Watson, Amsterdam.
46. Pfaffenrath V., et al. Magnesium in the prophylaxis of migraine-a double-blind placebo-controlled study. Cephalalgia 1996, 16:436-440.
47. Richter F., et al. Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J. Cereb. Blood Flow Metab. 2005, 25:1225-1235.
48. Russell M.B., Olesen J. Migrainous disorder and its relation to migraine without aura and migraine with aura. A genetic epidemiological study. Cephalalgia 1996, 16:431-435.
49. Sandor P.S., et al. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 2000, 40:30-35.
50. Schoenen J. Future Preventive Therapy: Are There Promising Drug Targets?. Headache Curr. 2006, 3:108-111.
51. Schoenen J., et al. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998, 50:466-470.
52. Silberstein S.D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754-762.
53. Sills G.J. Changing channels: mechanisms and responsiveness to antiepileptic drugs in chronic epilepsy. Epilepsy Curr. 2004, 4:98-99.
54. Skoglund T.S., et al. The existence of a layer IV in the rat motor cortex. Cereb. Cortex 1997, 7:178-180.
55. Smith M.E., et al. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia 2006, 47:695-703.
56. Smith M.I., et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 2000, 20:546-553.
57. Steiner T.J., et al. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997, 17:109-112.
58. Stovner L., et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007, 27:193-210.
59. Supornsilpchai W., et al. Involvement of pro-nociceptive 5-HT2A receptor in the pathogenesis of medication-overuse headache. Headache 2010, 50:185-197.
60. Tottene A., et al. Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice. Neuron 2009, 61:762-773.
61. van der Hel W.S., et al. Suppression of cortical spreading depressions after magnesium treatment in the rat. NeuroReport 1998, 9:2179-2182.
62. Weiller C., et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1995, 1:658-660.
63. Wolthausen J., et al. Are cortical spreading depression and headache in migraine causally linked?. Cephalalgia 2009, 29:244-249.
64. Zempleni J., et al. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am. J. Clin. Nutr. 1996, 63:54-66.